Myconormin (Terbinafine Hydrochloride)

Terbinafine Hydrochloride, the active ingredient in Myconormin, is a allylamine antifungal presented as an oral tablet for oral use. It treats fungal infections of the nail and skin in adult patients, targeting conditions such as onychomycosis and various tinea infections.

GNH USA supplies Myconormin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Myconormin is an allylamine antifungal used to treat infections caused by dermatophytes and yeasts. - Onychomycosis: reduces fungal growth in the nail plate, improving nail appearance and preventing spread. - Tinea pedis: alleviates foot skin infection, relieving itching and scaling. - Tinea corporis: clears body‑wall fungal lesions, restoring normal skin texture. - Tinea cruris: treats groin‑area fungal infection, reducing redness and discomfort.

Terbinafine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal pain, or dyspepsia. - Skin reactions: mild rash, pruritus, or erythema. - Taste disturbances: loss of taste or metallic taste.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or hepatitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hematologic changes: neutropenia or eosinophilia. - Peripheral neuropathy: tingling or numbness in extremities. - Anaphylaxis: rare but potentially life‑threatening allergic response.

Before initiating therapy, clinicians should consider several safety measures. - Assess liver function: obtain baseline hepatic enzymes and monitor periodically. - Evaluate hypersensitivity: avoid use in patients with known terbinafine allergy. - Monitor skin reactions: discontinue if severe rash or blistering occurs. - Use cautiously in the elderly: adjust monitoring due to potential comorbidities. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Terbinafine may interact with several co‑administered medicines, requiring attention to dosage and monitoring.

Major Interactions (Avoid): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase terbinafine plasma levels. - Rifampin or other strong CYP inducers: may reduce terbinafine effectiveness.

Moderate Interactions (Monitor Closely): - Warfarin: terbinafine can enhance anticoagulant effect, requiring INR monitoring. - Oral contraceptives: may decrease hormonal efficacy, consider alternative contraception. - Alcohol: concurrent use may increase risk of liver toxicity.